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Abstract
Objectives: A novel characterization of Clinically Isolated Syndrome (CIS) patients according to lesion patterns is proposed.
More specifically, patients are classified according to the nature of inflammatory lesions patterns. It is expected that this
characterization can infer new prospective figures from the earliest imaging signs of Multiple Sclerosis (MS), since it can
provide a classification of different types of lesions across patients.
Methods: The method is based on a two-tiered classification. Initially, the spatio-temporal lesion patterns are classified. The
discovered lesion patterns are then used to characterize groups of patients. The patient groups are validated using
statistical measures and by correlations at 24-month follow-up with hypointense lesion loads.
Results: The methodology identified 3 statistically significantly different clusters of lesion patterns showing p-values smaller
than 0.01. Moreover, these patterns defined at baseline correlated with chronic hypointense lesion volumes by follow-up
with an R2 score of 0:90.
Conclusions: The proposed methodology is capable of identifying three major different lesion patterns that are
heterogeneously present in patients, allowing a patient classification using only two MRI scans. This finding may lead to
more accurate prognosis and thus to more suitable treatments at early stage of MS.
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Introduction
Multiple Sclerosis (MS) is an acquired inflammatory, demye-
linating disease of the central nervous system. This disease is a
major cause of disability among young adults, and is very common
in the Northern Hemisphere. Moreover, the high evolution
heterogeneity among the patients renders it complex to encompass
and to predict at the individual level. Epidemiological and imaging
data are showing that MS is a two-phase neurodegenerative
inflammatory disease. The early stage is dominated by focal
inflammation of the white matter (WM), and the latter stage is
dominated by diffuse lesions of WM, gray-matter (GM) and spinal-
cord lesions [1,2]. Large epidemiological studies [1,3,4] bring out
clinical factors influencing disability during the first phase. These
include gender, age at disease onset, number of relapses within the
first 2 years and residual deficit after the first relapse. Unfortu-
nately, these factors do not enable prediction of the clinical course
at the individual scale. Furthermore, biological and imaging
examination still fail to predict accurately disease severity, nature
and progression for each patient. To this day, all treatments
available are mainly effective only during the early stage, and
many arguments suggest that early treatment with disease-
modifying drugs can reduce the risk of disability [5]. Because of
their significant side effects, some intensive treatments, which are
referred to immuno-suppressive drugs, are often used too late
[6,7]. In this context, there is a need for robust and specific
markers to characterize the pathology of MS patients and thus
identify at the earliest stage those with a high risk of experiencing a
more severe disease course in order to tailor the treatment at the
individual level [1,3,4].
The MS onset can be studied in Clinically Isolated Syndrome
(CIS) patients. These patients experienced an initial attack
suggestive of demyelination, but do not yet meet the criteria for
MS even though they are highly likely to develop it [8].
Macrophage infiltration is an important pattern in inflammatory
processes associated with MS. A close link between macrophage
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infiltration and axonal loss is indeed supported by several studies.
There is a spatial link between the presence of active macrophages
and axonal injury [9,10]. Macrophages synthesize free radicals
and cytotoxic proteins [11] that are known to cause axonal
destruction when they come in contact with brain tissue [12,13].
This axonal loss may be secondary to mitochondrial injury and
subsequent energy failure [14]. Moreover, axonal injury is a major
substrate for permanent neurological disability in patients [9,15].
This can be evaluated by monitoring patients at the onset of the
disease using a novel contrast agent, called Ultrasmall Super
Paramagnetic Iron Oxide (USPIO) sensitive to macrophages
activity, which has been recently used in preliminary studies in
human related to brain tumors, stroke, and MS [16–19].
Gadolinium (Gd) and USPIO do not highlight the same
phenomenon: Gd reveals non-specific blood brain barrier
breakdown, whereas USPIO highlights the inflammatory process
related to activated macrophages [16–19]. Recent studies have
suggested a link between USPIO enhancement patterns [18,19]
and the subsequent occurrence of chronic hypointense lesions.
Moreover, it has been demonstrated in MS that the T1
hypointense lesions are the site of higher axonal injury [20] and
correlate with disability, and to be more highly correlated with
disability than T2 lesions [21,22]. T2 lesions represent variable
degrees of demyelination, gliosis, axonal loss, edema and
inflammation, while hypointense lesions are more associated with
permanent tissue destruction and therefore have a better
correlation with disabilities [21]. All these elements suggest that
there is a close link between macrophage infiltration, axonal injury
and disability.
The use in MS of contrast agents specific of active macrophages
offers an opportunity to better understand the occurrence of
irreversible disability and could help to predict it. To our
knowledge, no previous study has been carried out using USPIO
on CIS patients. Moreover the current classification of patients is
based either on their total lesion load or disability index without
analyzing the specific lesions evolution, the proposed framework
aims at providing more specific figures. The overall challenge is to
propose a new clinical and data processing paradigm in order to
study MS at the disease onset, to provide a better understanding of
the early pathogenic mechanisms and to predict the disease
evolution at the patient level. In this context, we propose a new
framework, based on a two-tiered classification (a the lesion level,
followed by a patient level), to find spatio-temporal patterns in CIS
patients, using MRI volumes enhanced by USPIO and by Gd and
focusing on the longitudinal evolution of lesions. These clusters of
patterns are validated by means of statistical analysis, and a
correlation with future chronic hypointense lesion load after 21
months follow-up. T2 Total Lesion Load (TLL) by follow-up is
also reported for the sake of completeness. This validation is
relevant, as these figures correlate with long-term disabilities [21–
24].
Materials and Methods
Twenty-five CIS patients (17 women and 8 men), aged 32:9+8:6
years old at baseline were included between July 2009 and April 2011
in different French centers (Rennes, Marseille, Paris, Toulouse,
Reims) based on the following criteria: (i) age between 18 and 45; (ii)
occurrence of the first presumed inflammatory demyelinating event
in the central nervous system involving either the optic nerve, the
spinal cord, a brain hemisphere, or the brainstem; (iii) no previous
history of neurological symptoms suggestive of demyelination; (iv) no
possible alternative diagnoses (lupus erythematosus, antiphospholipid
antibody syndrome, Behcet’s disease, sarcoidosis, Lyme disease,
cerebral arteritis, brain lymphoma, etc.); (v) patients fulfilling at
least the dissemination in space criteria according to McDonald
et al [25]; (vi) Expanded Disability Status Scale (EDSS) [26]
between 0 and 5 at baseline (vii) first injection of USPIO within
three months after the first clinical episode; (viii) no corticoids in
the month before USPIO injection and no previous adminis-
tration of immunomodulatory or immunosuppressive drug; (ix)
no previous history of asthma, allergy, or injection of iron oxide
particles within the previous 5 months; (x) and no pregnancy.
MR imaging was performed within 3 months after the onset of
the disease in different hospitals using either a 3T Verio
(Magnetom, Siemens Medical Solutions, Erlangen, Germany) or
a 3T Achieva (Philips Medical Systems, Best, The Netherlands)
scanner according to a multi-center protocol. The protocol
contained axial 2D T1 SE sequences, pre, 5 minutes post Gd
injection and 24 hours post USPIO injection, with TR/TE 500/
8.4 ms, T2 TSE imaging with TR/TE 6530/84 ms, axial 2D
FLAIR with TR/TI/TE 10000/2600/80 ms and 3D FLAIR with
TR/TI/TE 5000/1800/273 ms. A 256|256mm2 Field Of View
was used to cover the whole brain with 44 3-mm 2D slices or a
1|1|3mm3 voxel size for 3D acquisitions. The imaging data
used in this study was acquired at baseline (m0), after 3 months
(m3), 12 months (m12) and 24 months (m24). The initial intervals of
three months are recommended in order to detect new active
lesions according to the temporal dissemination criteria [27,28].
The latter time points have been used as further validation.
Fourteen patients after m3 were diagnosed with clinical MS and
started undergoing treatments based on interferon beta-1-alpha
likely to interfere with the number and extension of lesions,
therefore the study limits the observation of the first two time
points in order to avoid any drug-related confounding cofactor.
Seven patients did not present any active lesions at the first two
time points. These patients were excluded from the clustering
described in the following sections, but their disease progression in
terms of future hypointense lesions and TLLs is also considered,
and they are discussed separately in the Discussion section.
Three neuroimage specialists [JCF, IB, AT] reviewed all images
independently and blindly from each other. Afterwards, the lesion
detections were compared reaching an agreement among the
specialists. Subsequently, a fourth physician [AM] performed the
manual annotations verifying again the lesions. The chronic
hypointense lesions [29] were assessed by analyzing [21] the T1
volumes of m12 and m24, defining a chronic hypointense lesion as
an hypointense lesion which is present at m24 and also visible at
m12. The follow-up TLLs were quantified on T2 volumes at m24.
The manual delineations on T2 volumes were also verified on
registered FLAIR volumes. The delineations were performed
using the MedInria paint tool [30] in a standardized protocol to
allow for reproducibility similar to [21]. After one month the
procedure was repeated in order to assess intra-observer variabil-
ity. The following subsections describe the representation of lesions
over time and the classification strategy.
Ethics Statement
The local institutional review board (Comite Consultatif de
Protection des Personnes dans la Recherche Biomedicale
[CCPPRB], Renns University hospital, France) approved the
protocol; and all participants gave their written informed consent.
Feature space
A specific feature space has been defined for each classification
tier: first for the lesion pattern classification, and then for the
patient classification. The overall work-flow described in the
following sections is depicted in Figure 1.
Multiple Sclerosis SpatioTemporal Lesion Evolution
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Tier 1: Lesion pattern features. Once the enhanced lesions
are manually delineated for all m time points (two in our case),
they are aligned according to their position at the first time point,
using the linear registration tool of MedInria [31]. Several features
were deemed to represent the shape evolution of the lesions, such
as the volume of each lesion, cell-inspired behavior [32], as well as
more advanced shape descriptors such as the Laplace-Beltrami
operator [33]. A tensor-like representation combined with a
hollowness index hi (see equation (1)) appeared to be the optimum
choice. Figure 2 depicts the process for a single lesion, and Figure 3
depicts examples of enhanced lesion patterns at different time-
points. The ordered eigenvalues of these 3D tensors yield a
rotationally invariant feature representation: for each lesion at
each time point, the coordinates of the n voxels belonging to a
specific lesion are collected in the data matrix X~½(x1{mx);
(y1{my); (z1{mz) j (x2{mx); (y2{my); (z2{mz) j . . . j (xn{mx);
(yn{my); (zn{mz) regardless of the intensity of the voxels. Here,
mx,my and mz are the mean of the coordinates for the n voxels of
each lesion, and the size of the matrix X is 3|n. These values are
used for defining a covariance matrix S~
1
n{1
XXT , which can
be decomposed in its eigenvalues L and eigenvectors V :
S~VLVT . The eigenvectors are neglected since the classification
is expected to be orientation invariant, while the eigenvalues can
represent the size of the lesions. This representation was also
chosen because 75% of the lesions have ellipsoidal shapes or can
be approximated by an ellipsoid. The remaining 25% have a ring
shape similar to a torus [19], which can also be approximated by a
tensor-like representation with same eigenvectors as if the central
holes would have been filled but slightly larger eigenvalues. To
uniform the representation, the ring-like shape has been consid-
ered as filled and the hollowness is measured and concatenated to
this information. We refer to the final section for further discussion





where Adelineatedi is the lesion area directly obtained by the manual
segmentation, and Afulli is the same area with filled holes. This
ratio should be 1 if there is no hole and becoming smaller than 1 if
a hole is present. The experiments were repeated also rounding
the hollowness measure to a binary value of either 0 or 1. All three
eigenvalues l contained in the diagonal of L and the hollowness
index for all m time points are the features representing the
temporal evolution of the lesions. This means that for each single
lesion, there is a feature vector fGd and fUSPIO given by
f ~½l01,l02,l03,h0,l11,l12,l13,h1, ð2Þ
containing the values respectively for the MRI volume Gd-
enhanced and USPIO-enhanced, in decreasing order for each
Figure 1. Classification work-flow showing all the steps of the proposed framework.
doi:10.1371/journal.pone.0093024.g001
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time point to be orientation independent, with li1§li2§li3 for
each of the m time point. Once the lesions are represented for both
contrast agents, the vectors fGd and fUSPIO of each lesion are
concatenated into a gGd{USPIO vector. If one lesion has only either
fGd or fUSPIO, the absence of the features is represented by zeros.
The same lesion present in different time points m, is aligned to the
other time representation of itself. This is performed by registering
linearly all the manual delineation volumes for the same patient to
the volume at the first time point [31]. If there is an overlap
between the lesions of the different time point, then they are
automatically considered to be the same lesion and collected into
the same g vector. The volumes are also visually inspected to verify
correct registration. In a further experiment the tensor-like
representation is also compared with a lesion volume representa-
tion for each time point, where the feature vector becomes
f ~½vol1,h0,vol1,h1 with voli representing the volume of a specific
lesion.
Tier 2: Patient features. The patient feature vector is given
by all the cardinalities of the lesion pattern clusters nCi learned
during the stage one for each patient q~½nC1, nC2, nC3 , e.g.
nCi ~2 when a lesion pattern is present twice, or nCi ~0 when a
lesion pattern does not exist for a given patient. The following
subsection describes how the lesion and final patient clusters are
obtained.
Lesion evolutions classification
The feature representations described in the previous subsec-
tions are used in a two-tier classification. Initially lesion patterns
are identified, then the discovered patterns are used to identify
specific patients which could potentially undergo a more severe
course. These two steps are performed by an unsupervised
clustering algorithm and a regression using the output of the first
tier as the input of the second, i.e. the detected lesion patterns q
are used as features for a second tier where a regression is
performed at the patient level.
K-means, hierarchical clustering and Gaussian Mixture Models
(GMM) are well-known unsupervised clustering algorithms [34].
K-means and GMM rely on estimating explicit data models.
Hierarchical clustering seeks to build a tree-like hierarchy of
clusters based on similarity criteria. These approaches generally
work, but they tend to fail when the nature of the data has a
complicated structure or the clusters have different sample sizes.
One way of coping with these issues, likely to arise in our case, is to
use spectral clustering [35]. This latest algorithm is based on the
point-to-point similarity matrix rather than on the estimate of an
explicit data model. Hence, spectral clustering is adopted as the
clustering algorithm in the proposed framework (classification
using only the K-means algorithm is also reported).
Yet the choice of cluster number needs to be predefined
arbitrarily. Since we are investigating the existence of possible
patterns, we have no prior knowledge of the number of clusters
and therefore we rely on some validity indices. Many validity
indices have been proposed, the reader can refer to [36] for a
comparison of some of them. The Dunn index sDunn [37] and the
Calinski-Harabasz index sCH [38] identify sets of clusters that have
a small within-cluster variance, and sufficient large between-cluster
variance. The Gap-statistics sGap [39] is given by a comparison of
the given data-set to an appropriate reference data set drawn from
an a priori distribution. The advantage of this validation is that it
does not assume the existence of at least 2 clusters, differently from
other methods. Another family of methods is strictly related to
spectral clustering [40], where the number of clusters sEigenGap is
discovered by analyzing the eigenvalues of the affinity matrix [41]
which represents the pairwise distances among all the samples. A
robust version of the approach was proposed for the case of noisy
or not well separated data [35]. Despite these methods generally
work, they do not represent a definitive answer to the challenge of
estimating the exact number of clusters and they do not necessarily
agree with each other. The choice of the index depends on the
nature of the data, on the subsequent used algorithm and on the
number of available samples. In absence of a priori knowledge
justifying the choice of one measure on the others, it is possible to
combine different measures since they can capture certain aspects
of a clustering solution [42] in a decision fusion as
Figure 2. The feature extraction process for a single time point. First all the lesions are delineated, then all the identified voxels are
considered to compute the hollow index h and to build the covariance matrix. Finally, the eigenvalues are obtained from this covariance matrix. The
process is repeated for all time points and the lesions which match at the different time point are ordered in the same feature vector.
doi:10.1371/journal.pone.0093024.g002
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where r is the number of used scores, and round() is an operator
which approximates a number to the nearest integer. In the
reported study, r~4 and the values of si are reported in Table 1.
Once the number of clusters is identified, spectral clustering [41]
coupled with K-means in the eigenspace is performed. It is worth
mentioning that with the self tuning spectral clustering implemen-
tation [35], it is possible to have a unique framework comprising
validity index, spectral representation and K-means. In the
reported experiments, all the mentioned validity indices are
computed as well as the decision fusion score (3). The final decision
fusion score is considered as the reference score, though the
existence of the resulting clusters is additionally validated as
described in the Statistical Analysis Section.
Patient classification
Once the clustering of the lesions patterns is performed, the
detected q vectors representing the cardinalities of the present
lesion patterns per patient can be used to identify specific patients.
The correlation between lesion patterns in patients and hypoin-
tense lesions is given to relate the patient classification to their
disease severity aiming at the prediction of the most severe cases. A
regression model [43] was used to examine the correlation
between the number of detected lesion patterns and the future
chronic hypointense lesion load:
l~b0zb1(nC1 )zb2(nC2 )zb3(nC3 ), ð4Þ
the coefficient b0 can be neglected because by construction of the
model there will be at least one non-zero nCi parameter, and l
represents the chronic hypointense for a specific patient. The
model examines the influence of the detected number of lesion
patterns, based on the assumption that some lesion patterns are
more indicative of disease severity [44]. The bi parameters were
estimated by minimizing the Least-Squares linear regression given
by
P
jjQB{Ljj2, where B is the vector containing all the bi, Q is
the matrix containing all the number of patterns per patient q and
L is a vector containing the relative hypointense lesion volume l.
Statistical analysis
The statistical significance of the lesion clusters is assessed by
computing the cluster separation [45], which is defined as the
average distance between each cluster centroid and the other
centroids similarly to the Dunn and the Calinski-Harabasz index,
and testing this measure against the Null hypothesis that these
clusters do not differ, similarly to the Gap-Statistics. More














where nC is the number of clusters, mck is the centroid of the
cluster Ck, d() is the distance used by the clustering, and s
2 is the
between-clusters variation obtained by pooling together the
samples of two different clusters examined in turn. The p-values
are computed for each cluster considering a rank analysis using
1000000 re-sampled permutations of cluster separation. Consid-
ering the different sample sizes of the obtained clusters, the p-
values were computed considering both cases of randomization
test and permutation test [47]. In the randomization test, all
samples are assigned to the clusters with no prior assumption. In
the permutation test, the number of samples per cluster is assumed
to be unchanged, though there is no evidence that the number of
samples within the clusters is correct.
The goodness of fit of a regression model can be assessed
through the R2 coefficient (also known as Coefficient of
determination) [43]. The R2 coefficient measures how well the
regression line approximates the real data points. An R2 of 1.0
indicates that the regression line perfectly fits the data. The most
general definition of the coefficient is
Table 1. Optimum number of clusters estimated on the tensor-like features using the different validity indices and the rounded
mean as described in Section 0 which represents the majority voting.
Feature n.clustersCH n.clustersDunn n.clustersGap n.clustersEigenGap n.cluster DFavg
fGd 2 2 1 3 2
gGd{USPIO 3 2 3 3 3
doi:10.1371/journal.pone.0093024.t001
Figure 3. The same lesion at the same time point: (a) Gd-enhanced, (b) USPIO-enhanced and (c) pre-contrast. It can be noticed that the
USPIO enhancements are generally very mild compared to the Gd enhancements.
doi:10.1371/journal.pone.0093024.g003
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where SSerr is the sum of squared differences between the predicted
L̂ and the reference L values. SSreg is the sum of squared differences
between the predicted values and the mean value of L. This
measurement is repeated in a leave one patient out cross-validation
manner, by repeating the computation removing one of the lesions
or one of the patient each time. The reported values are the mean
and variance of all the obtained R2 coefficients for both the cases of
used features gGd{USPIO and fGd only. The clusters obtained using
the gGd{USPIO features are also compared to the clusters obtained
using fGd only. This is assessed by computing p-values based on the
Z-scores of the samples means.
Results
In this section the results of the two-tiered classification are
reported. First the clinical observations are reported, and then the
results for the lesion pattern clusters and the patient groups.
Clinical results
The mean EDSS score of all twenty-five patients at baseline was
1:7+1:4. Fourteen patients were assessed RRMS according to the
McDonald 2005 criteria [25] already by m3, whereas four
converted to RRMS by m24. Of the seven patients which did
not present either Gd or USPIO active lesions at the two baseline
time points, only one was assessed RRMS by m24 and the
remaining six were still CIS by m24.
Comparing the manual annotations of the enhancement for
both contrast agents for the same lesions, the USPIO-enhanced
lesions show a different behavior than the Gd-lesions and are often
visible as a mild ringing around the Gd-lesions as depicted
in Figure 3.
Table 2. List of patients with the relative detected patterns, hypointense lesions volume and TLL in cm3 by follow-up (m18),
ordered according to chronic hypointense lesions volume.
Patient lesion clusters (and cardinality)
chronic hypointense at
m24 TLL by m24 Group
6 C2(|1), C3(|1), C1(|38) 13.40 cm3 18.9 cm3 A
24 no active lesions at m0 and m3 3.35 cm3 4.63 cm3 C
11 C1(|1) 1.80 cm3 9.70 cm3 B
4 C2(|1), C1(|2) 1.77 cm3 4.29 cm3 A
16 C3(|1) 1.46 cm3 4.70 cm3 A
9 C2(|1) 1.42 cm3 6.72 cm3 A
10 C2(|2), C1(|8) 1.37 cm3 4.82 cm3 A
25 C1(|2) 0.96 cm3 3.32 cm3 B
7 C1(|9) 0.82 cm3 2.10 cm3 B
18 C1(|4) 0.75 cm3 3.40 cm3 B
21 C1(|2) 0.74 cm3 3.50 cm3 B
17 C1(|1) 0.52 cm3 1.18 cm3 B
2 C1(|1) 0.46 cm3 1.90 cm3 B
12 C1(|6) 0.34 cm3 2.10 cm3 B
8 C1(|1) 0.31 cm3 1.14 cm3 B
3 no active lesions at m0 and m3 0.28 cm3 0.98 cm3 C
19 C1(|1) 0.27 cm3 1.73 cm3 B
20 no active lesions at m0 and m3 0.18 cm3 0.54 cm3 C
5 C1(|2) 0.14 cm3 1.70 cm3 B
15 no active lesions at m0 and m3 0.13 cm3 0.68 cm3 C
13 C1(|2) 0.12 cm3 3.54 cm3 B
1 no active lesions at m0 and m3 0.12 cm3 1.18 cm3 C
22 C1(|4) 0.10 cm3 1.27 cm3 B
23 no active lesions at m0 and m3 0.06 cm3 0.49 cm3 C
14 no active lesions at m0 and m3 0.00 cm3 0.29 cm3 C
The last column pinpoints the different patient groups. Patients of Group A present at least one lesion pattern belonging either to the cluster C2 or to the cluster C3 ,
which it is considered an indication of severe condition. Patients of Group B do not present any lesion pattern either C2 or C3 . The patients of Group C are the patients
which do not present active lesions at the first two time points.
doi:10.1371/journal.pone.0093024.t002
Multiple Sclerosis SpatioTemporal Lesion Evolution
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The expert radiologist manually delineated 103 Gd-lesions
and 24 USPIO-lesions. Only one lesion was enhanced
by USPIO and not Gd, such a lesion pattern was grouped in the
cluster C1 described in the following section. By examining which
of the active lesions converted to hypointense lesions by m24, it was
noted that generally half of USPIO-enhanced ringing lesions
converted to hypointense lesions at m24 while the other half
appeared to recover to isointense, whereas 80% of Gd-enhanced
are reported per patient in Table 2. The intra-observer variability
was assessed by computing an intraclass correlation coefficient of
the hypointense lesion load, which gave a value of 0.88.
Results lesion pattern classification
The clinical value of USPIO is assessed comparing the results
obtained using the gGd{USPIO vectors which contain both the Gd
and USPIO features and the fGd which contain the Gd values
only. The comparison to the fUSPIO vectors is not feasible because
the matrix containing the collection of such vectors will be very
sparse. In fact, due to the small number of USPIO lesions
compared to Gd lesions, the matrix will be full of zeros and with
very few values. Such a matrix is not usable from the algorithms
used here for the classification since it is pseudo-singular. A first
comparison was performed by computing the validity indices
respectively for both representations as reported in Table 1.
Although it seems there is no clear agreement about the optimal
number of clusters according to the different validity indices, there is
generally an increase of cluster number using the gGd{USPIO vectors
rather than using the fGd vectors containing only the Gd features.
This increase is not related to the increase of dimension - as it can be
easily proved using artificial-data - but rather to differences
arising from the variable image signatures between the two
contrasts agents used jointly. Since the rounded mean of the
scores is 3, it is assumed that there are 3 clusters and their
presence will be validated as described in the Statistical Analysis
section.
The pipeline results highlight whether the same patient has
multiple lesions belonging to different lesion clusters Ci. The first
identified cluster is the less specific and it comprises different kinds
of lesion patterns with similar behaviors while the other two
clusters are more specific:
N C1 comprises lesions of different sizes (small, medium, large)
appearing at the first time point m0 and then disappearing at
m3, similarly as observed previously [19], and generally only
Gd-enhanced (this is the most common pattern observed).
Figure 4 depicts a typical example belonging to this cluster.
N C2 includes relatively medium and large lesions present at both
the first two time points with co-presence of USPIO and Gd,
where the Gd-enhanced lesions are focal and the USPIO-
enhanced lesions have a ringing behavior. Figure 5 depicts a
typical example belonging to this cluster.
N C3 comprises relatively medium lesions present mainly at the
first time point where the USPIO and Gd lesions were both
non-focal (ringing or non completely focal) and approxima-
tively of the same size. Figure 6 depicts a typical example
belonging to this cluster.
This shows that the clusters differentiate the co-presence of both
contrast agents, and not only the size of the lesions.
The statistical significance assessed by the cluster separation
[45], for the randomization tests showed for all the clusters a p-
value v0:0001. For the permutation tests the p-values were
p(C1)~0:0001, p(C2)~0:0021, and p(C3)~0:0192.
The experiment was repeated using 1) the Gd features only still
using the tensor-like measurements; 2) for both Gd and USPIO
features and only Gd using the simpler representation given by the
volume of lesions for each time point; 3) using K-means in place of
the Spectral clustering algorithm. All these last variations of the
experiment produced only two clusters with one cluster comprising
relatively large and medium lesions by m0 and the other cluster
only small lesions. In these variations, the clusters comprising the
large and medium lesions were generally larger than the cluster
obtained using the main settings (tensor-like representation, both
contrast agents and spectral clustering). In fact the lesion patterns
comprised by the C2 and C3 clusters obtained by the main settings
were only 7, and the cluster C1 comprised 84 lesion patterns; while
with the other settings there were about 20 in the cluster with large
and medium lesions and 71 in the remaining cluster.
Results patient classification
The volume of chronic hypointense lesions - reported in Table 2
- are used to classify patients and to build the regression model of
equation (4). Moreover, the table depicts how the lesion patterns
correlate with the future volume of the hypointense lesions and
TLLs also computed at m24, only patients 11 and 24 do not seem
to correlate. The classifications have been carried out in a cross-
validation manner as well, iteratively removing each time a lesion
pattern. The patient groups are also graphically represented
according to their chronic hypointense lesion and TLL by m24 in
Figure 7.
Figure 4. Illustration of a spatio-temporal evolution of the
same lesion for both contrast agents and pre-contrast
belonging to C1. In general, C1 is the less specific which comprises
lesions of different dimensions (small, medium, large) appearing at the
first time point m0 and then disappearing, and generally Gd-enhanced
only.
doi:10.1371/journal.pone.0093024.g004
Figure 5. Illustration of a spatio-temporal evolution of the
same lesion for both contrast agents and pre-contrast
belonging to C2. In general, C2 includes relatively medium and large
lesions present at both the first two time points, and with co-presence
of ringing USPIO and focal Gd enhancement.
doi:10.1371/journal.pone.0093024.g005
Figure 6. Illustration of a spatio-temporal evolution of the
same lesion for both contrast agents and pre-contrast
belonging to C3. In general, C3 comprises relatively medium lesions
present mainly at the first time point with non focal USPIO and Gd
enhancement.
doi:10.1371/journal.pone.0093024.g006
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focal lesions converted to hypointense lesions. The lesion volumes
Table 3 summarizes the correlation coefficients for the different
settings given by the used features and algorithms. The mean R2
coefficient computed using the equation (6) performed in a cross-
validation manner was of 0:90+0:05. Repeating the entire
experiments for 2 clusters using the fGd features only (variation
1), the lesion patterns were partitioned into large and medium
lesions together at m0 and small lesions at m0 as described in the
previous section, and the obtained R2 coefficient was 0:86+0:08.
No difference was noticed regarding the use of a continuous
measure of the hollow-index and a binary definition as ring-like or
filled lesion (namely 0 for ring-like lesions and 1 for filled lesions).
The experiments using the volume features for both contrast agent
Gd and USPIO and GD only (variation 2) produced the following
R2 coefficient respectively: 0:86+0:08 and 0:80+0:13. Whereas
using only the K-means algorithm (variation 3) yielded 0:86+0:08
and 0:86+0:07.
Discussion
The proposed framework is capable of classifying lesions and
MS patients from the very early stages onwards (first 2 MR scans,
prior to any drug prescription). This classification correlates closely
with the volume of hypointense lesion voxels and to the T2 TLL
by m24. Hypointense lesions represent severe and irreversible
tissue destructions which is deemed to correlate to future
disabilities [21,22]. Although less strongly than hypointense
lesions, T2 lesions load is considered a predictor figure of future
disabilities as well [23,24]. Moreover USPIO-enhanced lesions
show different behaviors than Gd-enhanced lesions. This leads to
the hypothesis that USPIO can help to mark lesions with a high
risk to decline to a more severe disease course. The proposed
machine-learning framework highlighted three main lesion clusters
(C1, C2 and C3). Among them, two were related to a higher TLL
and hypointense lesions at m24. These two components (C2 and
C3) correspond to relatively larger lesions enhanced by USPIO
and Gd, in agreement with recent radiological findings showing
that lesions enhanced by both contrast agents at baseline were
larger and were more likely to persistently enhance at 6-month
follow-up compared with those that enhanced only with Gd or
USPIO [18].
The R2 correlation coefficients obtained using both the tensor-
like Gd and USPIO features were larger than using the Gd
features only. However, studies featuring larger populations are
required to fully validate this hypothesis. Nevertheless, we can
hypothesize that the disease severity is related to the presence of
certain lesion patterns rather than others, in particular to the
presence of the lesion patterns C2 and C3, which correspond to
very large and active lesions (enhanced by both contrast agents) at
the disease onset. By contrast, as expected, patients with only one
lesion pattern C1 have very few future hypointense lesions and
very low TLLs by m24. In fact, this characterization suggests as
well that having a specific lesion pattern has an incidence on the
future evolution of the disease. Since EDSS correlates to lesion
load after several years [21,22,24].
Moreover, from these observations, it may be hypothesized that
not all the lesions - even if enhanced by Gd - contribute in the
same way to the worsening of the disease. Disability may not be
directly related to a blood brain barrier breakdown, but rather to
how the brain overall copes with the damages generated by MS
[44]. The presence of specific lesion patterns with co-presence of
both Gd and USPIO may be indicative of a more severe course
represented by more hypointense lesions and relatively large TLL.
The number of active lesions does not necessarily provide such
information, therefore a regression model based on the detected
clusters - similarly to [48] - was devised.
Contrary to [17–19], more Gd-enhanced lesions than USPIO-
enhanced lesions were detected. This difference could be
motivated by one or more of the following reasons:
N Different cohorts are used. In previous studies, the patients
were at a more advanced stage of the disease (RRMS or
progressive MS). Moreover, Vellinga et al. [19] included
patients with active lesions on MRI and Dousset et al. [17]
included patients with active relapse.
N Most of the RRMS patients may be under treatment, which
reduces the number of Gd-enhanced lesions.
N The studies have different time interval between MRI scans.
Table 3. R2 coefficients for different algorithms and features used.
Settings R2 using Gd and USPIO feat. R2 using Gd feat. only
Tensor-like feat. and Spectral clustering 0:90+0:05 0:86+0:08
Volume feat. and Spectral Clustering 0:86+0:08 0:80+0:13
Tensor-like feat. and K-means 0:86+0:08 0:86+0:07
Volume feat. and K-means 0:82+0:07 0:80+0:13
doi:10.1371/journal.pone.0093024.t003
Figure 7. Patients according to their chronic hypointense
lesions and TLLs by m24. The red stars are patients of Group A
reported in Table 2 which presented at least one lesion pattern C2 or
C3 , the green diamonds are the patients of Group C with no active
lesions at the two time points, and the black circles are the reminding
patients of Group B.
doi:10.1371/journal.pone.0093024.g007
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The observation that generally half of USPIO-enhanced ringing
lesions converted to hypointense lesions at m24 while the other half
tends to recover to isointense, whereas 80% of Gd-enhanced focal
lesions with no USPIO enhancement converted to hypointense
lesions, is partially in line with the results reported in [19],
suggesting that some cases - namely USPIO-enhanced ring-like
lesions - exhibit a return to isointense lesions. However, the
patients presenting at least either one C2 or C3 lesion pattern seem
to have more hypointense lesions by m24, this is probably related
again to the fact that these patterns indicate high activity [18].
Beyond the clinical validation, the classification method itself is
significantly novel and of general relevance independently from
the specific data-set.
The tensor-like representation for lesions is motivated by the
rotationally invariant eigenvalues and the analogy to PCA. The
detected clusters proved to be statistically significant in our dataset.
However, both the tensor-like and volumetric representation can
oversimplify the complexity of the lesion enhancement even if still
informative. To complement this representation a clear indication
of the hollowness of the lesion has been added in such a way to
discriminate focal from ringing-like lesions. Future works can
comprise to use features obtained using the Laplace-Beltrami
operator [33] which could simplify the issue of the hole in the
ringing lesions, other MRI quantitative measurements (such as
Magnetization Transfer, Diffusion MRI or relaxometry), and
evolution in terms of brain atrophy [49]. In summary, the
proposed approach can provide an additional classification of the
different types of lesions across patients not provided by lesion load
measurement only. This new insight could contribute to patient
selection for therapeutic trials focusing on preventing or delaying
the development of MS and related disabilities.
Conclusion
A novel paradigm for spatio-temporal analysis of MS lesions at
disease onset has been proposed. It has been applied using a novel
contrast agent (USPIO) yielding complementary information
compared to Gd. We devised a two-layer classification, first
identifying lesion patterns then classifying patients in terms of
predictive risk of disease progression according to the lesion
patterns. Such an approach is very interesting as it allows to relate
parameters extracted from patient images to invisible disease
parameters such as future course of the disease.
This patient classification performed at the very early clinical
stages of MS correlates closely with hypointense lesions and TLLs
by m24, indicating a probable more severe evolution [21,24]. This
finding could lead to a more precise and early prognosis at onset,
and therefore to more adapted treatments according to the patient
risk profile.
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